Article Text

PDF
Veterinary Medicines
Veterinary medicines: product update

Statistics from Altmetric.com

The following information has been produced for Veterinary Record by the Veterinary Medicines Directorate (VMD) to provide an update for veterinary surgeons on recent changes to marketing authorisations for veterinary medicines in the UK and other relevant issues.

THE points below highlight changes in marketing authorisations that may have a significant impact on veterinary surgeons' prescribing decisions.

New marketing authorisations

New marketing authorisations that have been issued in October 2011 are listed in Table 1. Table 2 shows the products that were authorised by the European Centralised Authorisation process in September 2011 but were not included in last month's report as the VMD was only made aware of the publication of the Commission decisions on them this month.

View this table:
Table 1

Marketing authorisations issued in October 2011

View this table:
Table 2

European Centralised Authorisations granted in September 2011 but not previously reported

Of the products in Tables 1 and 2, one (highlighted in blue type) contains an active ingredient not previously included in an authorised veterinary medicinal product in the UK – Nobivac Myxo-RHD, which contains live myxoma vectored rabbit haemorrhagic disease virus.

These products may not yet be readily available in the UK. Veterinary surgeons should contact the marketing authorisation holder directly for details of supply.

Tables 1 and 2 also indicate where a public assessment report should become available for a product on the VMD's website. Where available, links to these reports are accessible by clicking on the relevant product on the VMD's Product Information Database, www.vmd.defra.gov.uk/ProductInformationDatabase/

The European Medicines Agency publishes European Public Assessment Reports for every veterinary medicine that is authorised through a centralised procedure. Links to these reports are accessible at www.ema.europa.eu

Marketing authorisation variations

The following clinically significant variations to marketing authorisations have been approved and/or published during October 2011:

■ Furexel Combi Oral Paste.

The indications have been updated to include activity against adult …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.